Amphastar Pharmaceuticals, Inc.
AMPH
$30.50
$0.842.83%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -2.77% | 8.18% | 20.13% | 24.34% | 23.11% |
| Total Other Revenue | -- | -- | -102.03% | -91.66% | -- |
| Total Revenue | -4.38% | -0.76% | 4.73% | 5.90% | 25.17% |
| Cost of Revenue | 0.80% | 4.33% | 21.85% | 23.73% | 19.53% |
| Gross Profit | -9.12% | -5.38% | -9.87% | -5.96% | 30.83% |
| SG&A Expenses | 8.65% | 11.24% | 7.46% | 24.95% | 17.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.97% | 7.60% | 13.90% | 24.37% | 16.87% |
| Operating Income | -23.60% | -22.32% | -16.37% | -21.51% | 49.66% |
| Income Before Tax | -21.71% | -34.76% | 7.64% | -24.61% | 54.56% |
| Income Tax Expenses | -32.45% | 35.17% | 28.35% | -48.28% | 92.61% |
| Earnings from Continuing Operations | -18.23% | -41.44% | 4.97% | -17.86% | 45.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.23% | -41.44% | 4.97% | -17.86% | 45.26% |
| EBIT | -23.60% | -22.32% | -16.37% | -21.51% | 49.66% |
| EBITDA | -16.92% | -16.54% | -12.31% | -17.41% | 59.01% |
| EPS Basic | -14.82% | -40.74% | 4.92% | -17.73% | 43.77% |
| Normalized Basic EPS | -18.46% | -33.97% | 7.61% | -24.49% | 52.99% |
| EPS Diluted | -12.33% | -37.04% | 7.17% | -14.29% | 48.98% |
| Normalized Diluted EPS | -15.33% | -30.68% | 11.21% | -21.62% | 57.68% |
| Average Basic Shares Outstanding | -4.00% | -1.18% | 0.04% | -0.16% | 1.04% |
| Average Diluted Shares Outstanding | -7.53% | -5.89% | -3.21% | -3.82% | -1.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |